NOVO-B.CO - Novo Nordisk A/S

Copenhagen - Copenhagen Real Time Price. Currency in DKK
285.20
+1.00 (+0.35%)
At close: 4:59PM CEST
Stock chart is not supported by your current browser
Previous Close284.20
Open286.00
Bid285.55 x 0
Ask285.70 x 0
Day's Range284.55 - 289.30
52 Week Range249.60 - 354.80
Volume1,874,357
Avg. Volume2,979,577
Market Cap693.062B
Beta0.60
PE Ratio (TTM)18.53
EPS (TTM)15.39
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est330.43
  • GlobeNewswire7 days ago

    Novo Nordisk A/S - Share repurchase programme

    Bagsværd, Denmark, 16 April 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...

  • GlobeNewswire14 days ago

    Novo Nordisk A/S - Share repurchase programme

    Bagsværd, Denmark, 9 April 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...

  • Novo Nordisk Obtains Licence for Sickle Cell Disease Program
    Zacks17 days ago

    Novo Nordisk Obtains Licence for Sickle Cell Disease Program

    Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

  • Reuters18 days ago

    Novo Nordisk buys blood drug licence to boost anaemic biopharma business

    Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) programme in a bid to offset declining sales in its biopharmaceutical business. Novo, best known for its diabetes drugs, is on the hunt for promising assets to boost its struggling blood products business after it lost out to French rival Sanofi in the chase for Belgian biotech company Ablynx in January. "This is a great opportunity for Novo Nordisk to enter into a new therapeutic area closely related to our existing biopharmaceutical business," said chief scientific officer Mads Krogsgaard Thomsen.

  • GlobeNewswire20 days ago

    Status regarding Novo Nordisk's holding of its own shares (31 March 2018)

    Bagsværd, Denmark, 3 April 2018 - In continuation of the company`s announcements dated 1 November 2017 and 5 February 2018 concerning planned share repurchase programmes, and pursuant to Section 204.25 ...

  • GlobeNewswire28 days ago

    FDA approves inclusion of data on cardiovascular outcomes and severe hypoglycaemia in the Tresiba® label

    Bagsværd, Denmark, 26 March 2018 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an update to the US prescribing information for Tresiba ® (insulin degludec) ...

  • These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status
    Investor's Business Dailylast month

    These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status

    A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.

  • GlobeNewswirelast month

    Ozempic® approved in Japan for the treatment of type 2 diabetes

    Bagsværd, Denmark, 23 March 2018 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ozempic ® (semaglutide), a new once-weekly analogue of human glucagon-like ...

  • Reuterslast month

    Drugmaker Novo Nordisk looks to former oil boss to energise M&A

    Leading diabetes drugmaker Novo Nordisk (NOVOb.CO) has named former oil boss Helge Lund as its new chairman as the company contends with increasing price pressure and seeks acquisitions to broaden its blood products line-up. The man dubbed by some as Norway's Mr Oil because of his extensive career in the oil and gas industry may be more of an expert in hydrocarbons than insulin, but his merger and acquisitions experience is a big draw for the Danish pharmaceuticals company.

  • Novo Nordisk Poised on Strong Pipeline Amid Competition
    Zackslast month

    Novo Nordisk Poised on Strong Pipeline Amid Competition

    Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.

  • Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
    Zackslast month

    Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns

    Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.

  • GlobeNewswirelast month

    Novo Nordisk A/S: Share repurchase programme

    Bagsværd, Denmark, 12 March 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...

  • Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices
    Bloomberg2 months ago

    Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices

    Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets." (Source: Bloomberg)

  • Reuters2 months ago

    Novo Holdings launches $165 million 'superbug' drug venture fund

    A $165 million (£119 million) venture fund focused on tackling "superbugs" resistant to modern antibiotics has been launched to invest in small companies working on novel medicines. Backed by Novo Holdings, which has big stakes in Danish drugmaker Novo Nordisk and enzymes specialist Novozymes, the new Repair Impact Fund will invest $20-40 million a year over three to five years in about 20 projects in Europe and the United States. Novo said on Wednesday its new fund would invest in start-ups, early-stage companies and corporate spin-outs, either as the sole investor or in a syndicate.

  • Reuters2 months ago

    Novo Nordisk successfully kicks off final-stage trials for first diabetes pill

    The world's largest diabetes drugmaker Novo Nordisk on Thursday presented the first successful data from a final-stage study for a pill it hopes will transform the diabetes market. The oral form of the drug, known generically as semaglutide, is crucial for ensuring the group's long-term growth, as price pressure has been mounting in a crowded market targeting the world's 450 million diabetics. Novo Nordisk said the first of 10 phase III trials were successful in its primary objective by demonstrating "significant and superior" improvements in long-term blood sugar compared to a placebo.

  • GlobeNewswire2 months ago

    Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide

    Bagsværd, Denmark, 22 February 2018 - Novo Nordisk today announced the headline results from PIONEER 1, the first phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral ...

  • Reuters2 months ago

    Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

    Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity. Novo Nordisk, the world's biggest insulin maker, launched Ozempic, known generically as semaglutide, in the United States this year after it was approved by the U.S. Food and Drug Administration in December. Ozempic is a once-weekly injection that Novo Nordisk hopes will take market share from Trulicity, which has been cutting into sales of Novo Nordisk's once-daily Victoza.

  • The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal

    The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal

  • GlobeNewswire2 months ago

    Novo Nordisk A/S - Share repurchase programme

    Bagsværd, Denmark, 19 February 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...

  • Top Research Reports for Novo Nordisk, TJX Companies & Cigna
    Zacks2 months ago

    Top Research Reports for Novo Nordisk, TJX Companies & Cigna

    Top Research Reports for Novo Nordisk, TJX Companies & Cigna

  • Motley Fool2 months ago

    5 More Stocks to Buy to Feed the Bear

    When the market is rising, Fools invest. But when the market is falling, Fools keep investing.

  • CNBC2 months ago

    FDA approves insulin dose calculator that's connected to a smartphone app

    The Food and Drug Administration has approved Glooko's Mobile Insulin Dosing System.

  • GlobeNewswire2 months ago

    Trading in Novo Nordisk shares by board members, executives and associated persons on 12 February 2018

    Bagsværd, Denmark, 13 February 2018 - This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company`s board members, executives and their associated persons in accordance ...

  • Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices
    Bloomberg Video2 months ago

    Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices

    Mar.02 -- Novo Nordisk CEO Lars Fruergaard Jorgensen discusses challenges facing the drug industry, the U.S. healthcare system and Brexit. He speaks on "Bloomberg Markets."